The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksUpdated×2•Originally published 6 May 2026•Updated 8 May 2026•

1 min read

Odyssey Therapeutics Prices Initial Public Offering at $18.00 Per Share

Key Facts

1InflaRx announced the pricing of its public offering of 75,000,000 ordinary shares at $2.00 per share.

Odyssey Therapeutics has announced the pricing of its initial public offering (IPO) of 15,500,000 shares at $18.00 per share, highlighting a resurgence in biotech financing. In a related sector development, Pharvaris announced the pricing of a $115 million underwritten offering of ordinary shares at $29.68 per share. Pharvaris has also granted underwriters a 30-day option to purchase up to an additional 581,199 ordinary shares. These capital raises are earmarked for advancing clinical pipelines and supporting general corporate activities. Market participants are closely monitoring these debuts to gauge investor appetite for high-growth biopharmaceutical firms. This activity follows a shift in the sector's landscape, contrasting with earlier secondary offerings from companies like InflaRx.

Sources:

27 days ago

Version History

Version 227 days ago

What changed: The story was updated to include details of Pharvaris's $115 million share offering, expanding the scope to cover broader biotech sector financing activity.

Version 127 days ago

What changed: The story was updated to reflect the initial public offering of Odyssey Therapeutics instead of the previous secondary offering by InflaRx.